U.S. markets closed

Ocular Therapeutix, Inc. (OCUL)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
8.21-0.25 (-2.96%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close8.46
Open8.53
Bid8.21 x 3100
Ask8.23 x 900
Day's Range8.03 - 8.78
52 Week Range2.46 - 9.27
Volume780,529
Avg. Volume954,009
Market Cap515.37M
Beta (5Y Monthly)1.54
PE Ratio (TTM)N/A
EPS (TTM)-2.01
Earnings DateAug 07, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates
    Zacks

    Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates

    Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -6.25% and -1.94%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

  • Benzinga

    Ocular Therapeutix: Q2 Earnings Insights

    Shares of Ocular Therapeutix (NASDAQ:OCUL) moved higher by 1% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share were down 12.28% year over year to ($0.64), which missed the estimate of ($0.31).Revenue of $1,569,000 rose by 141.38% year over year, which beat the estimate of $1,500,000.Looking Ahead Earnings guidance hasn't been issued by the company for now.Ocular Therapeutix hasn't issued any revenue guidance for the time being.Conference Call Details Date: Aug 07, 2020View more earnings on OCULTime: 08:30 AMET Webcast URL: https://edge.media-server.com/mmc/p/ze3bnc2dTechnicals Company's 52-week high was at $9.27Company's 52-week low was at $2.46Price action over last quarter: Up 32.57%Company Profile Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Ocular Therapeutix aims to offer medication to replace the existing eye-drop therapy regimen, with the aim of lasting weeks or months with a one-time product application. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, PTX-TP, and OTX-IVT.See more from Benzinga * Earnings Scheduled For August 7, 2020 * Earnings Outlook for Ocular Therapeutix * Stocks That Hit 52-Week Highs On Wednesday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Ocular Therapeutix™ Reports Second Quarter 2020 Financial Results and Business Update
    Business Wire

    Ocular Therapeutix™ Reports Second Quarter 2020 Financial Results and Business Update

    Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the second quarter ended June 30, 2020 and provided a business update.